Nitazoxanide is active against Mycobacterium leprae

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Nitazoxanide (NTZ) is an established anti-parasitic agent with known activity against Mycobacterium tuberculosis.
• Leprosy, caused by Mycobacterium leprae, remains a significant global health challenge requiring effective treatments.

Purpose of the Study:

• To investigate the in vitro and in vivo efficacy of Nitazoxanide (NTZ) against Mycobacterium leprae.
• To evaluate NTZ as a potential therapeutic agent for leprosy treatment.

Main Methods:

• In vitro studies utilized radiorespirometry and live-dead staining to assess NTZ's bactericidal activity against M. leprae.
• In vivo efficacy was evaluated in M. leprae-infected mice treated with NTZ via gavage.

Main Results:

• In vitro data confirmed that NTZ exhibits bactericidal activity against M. leprae.
• In vivo studies showed that NTZ at 25mg/kg conferred anti-mycobacterial activity equivalent to rifampicin (RIF) at 10 mg/kg in infected mice.

Conclusions:

• Nitazoxanide demonstrates significant anti-mycobacterial activity against M. leprae, both in vitro and in vivo.
• NTZ shows comparable efficacy to rifampicin in a murine model, supporting its consideration for leprosy treatment regimens.